<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>IMBS second day by Barbara Ghiglione</title>
      <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn</link>
      <description>Made with joy</description>
      <language>en-us</language>
      <pubDate>2020-10-13 20:51:27 UTC</pubDate>
      <lastBuildDate>2020-10-14 14:01:24 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Kpn ST258</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826650743</link>
         <description><![CDATA[<div><strong>1. Worldwide dissemination</strong></div><ul><li>Kpn <mark>ST 258</mark> high-risk clone</li><li>Plasmid IncFII Tn4401</li><li>KPC-2 and KPC-3 (KPC-2 + H272Y)</li></ul><div><strong>2. R</strong>: To all Beta-lactams, including <mark>CARBAPENEMS</mark></div><div><strong>3. Co-R</strong>: AG, COL, FQ, impermeability<br><strong>4.</strong> <strong>Virulence (More?)</strong></div><div>pilV on ICEKp258.2 (transmissibility and survival)</div><div><strong>5. Virulence (Less?)</strong></div><div>ST258 lacks </div><ul><li> K1, K2, and K5 capsular antigen genes</li><li>aerobactin genes</li><li> regulator of mucoid<br>phenotype gene, rmpA</li><li> (is nonvirulent in animal models, is highly susceptible to<br>serum killing, and can rapidly undergo phagocytosis)</li></ul>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 20:57:02 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826650743</guid>
      </item>
      <item>
         <title>Kpn ST307</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826722400</link>
         <description><![CDATA[<div><strong>1. Worldwide dissemination</strong></div><ul><li>KPC, NDM, OXA-48, VIM</li><li>Usually associated to CTX-M-15</li></ul><div><strong>2.</strong> <strong>Virulence (More or less?)</strong><br>Several virulence factors, different from ST258.<br><mark>Evidence for increased virulence and fitness of ST307 when compared to other K.<br>pneumoniae clones or isolates, is currently lacking</mark></div><div><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 21:34:37 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826722400</guid>
      </item>
      <item>
         <title>Changing epidemiology in Argentina (and the world?)</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826771273</link>
         <description><![CDATA[<div>1. In Argentina, ST258 is not prevalent any more<br>2. Dissemination of more virulent lineages: </div><ul><li>hypermucoviscous ST25 </li><li> high-risk clone ST307 and occurrence of blaKPC-3 </li><li><em>bla</em>KPC-3 can conduce to variants with significantly reduced ceftazidime-avibactam susceptibility.</li><li><mark>low virulent ST258/capsulated ST307  (higher R to complement-mediated killing).</mark></li><li>ST307 clone harbours a cluster for glycogen synthesis,  long-term survival and growth in environments outside the host</li></ul><div><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 22:03:48 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826771273</guid>
      </item>
      <item>
         <title>Kpn ST258 KPC-3 producers CAZ/AVI R intratreatment</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826798157</link>
         <description><![CDATA[<div><strong>1. KPC-3</strong></div><ul><li>9-30 &gt; kcat/Km than KPC-2 CAZ</li><li>omega loop 165-179</li></ul><div><strong>2. CAZ/AVI R mutants<br></strong>D179Y/T243M &gt; D179Y &gt; V240G</div><ul><li><mark>omega-loop substitutions  enhance ceftazidime affinity, which may prevent binding of AVI (CAZ IMPACT, NOT AVI)</mark></li><li>CARBAPENEM S</li></ul><div>3. KPC-3 predisposition factor?<br>4. Combination therapy with carbapenems?</div>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 22:21:30 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826798157</guid>
      </item>
      <item>
         <title>More CAZ/AVI R KPC-3 mutants</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826823499</link>
         <description><![CDATA[<div>D179Y, T243M, D179Y/T243M, and EL165-166<br>&gt;MICs CAZ/AVI<br>&lt;MICS CARBAPENEMS (other beta-lactams)<br><strong><mark>OMEGA LOOP HIGHER IMPACT<br></mark></strong>Combination therapy with carbapenems?</div>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 22:39:10 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826823499</guid>
      </item>
      <item>
         <title>KPC-41 (PNK269270)</title>
         <author>barbaraghiglione</author>
         <link>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826831056</link>
         <description><![CDATA[<div>NOT OMEGA LOOP IMPLICATION<br>&gt; CAZ affinity<br>&lt; Susceptibility to AVI<br>&lt; Carbapenemase activity<br><br><strong>Circulating strains! Not intratreatment selection!<br>Still detectable by phenotypic tests (ertapenem hydrolisis)</strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2020-10-13 22:44:48 UTC</pubDate>
         <guid>https://padlet.com/barbaraghiglione/vnmady22wggmb2qn/wish/826831056</guid>
      </item>
   </channel>
</rss>
